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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma is caused by several factors such as infections of Epstein Barr Virus 
(EBV), it has also been exaggerated by the genetic factors such as, HLA-A2, and environmental factors such as 
nitrosamines and the presence of polymorphisms of CYP2E1 gene that activates nitrosamines as pro oncogenes. 
Objective: To analyse the relationship between HLA-A2 expression, gene polymorphisms of CYP2E1 and 
nitrosamine levels in patients with nasopharyngeal carcinoma in Makassar. 
Methods: This research is analytic observational with cross-sectional design. Examination of HLA-A2 
expression with immunohistochemical methods was conducted, along with genotyping CYP2E1 gene with 
Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphism (RLFP), and levels of 
nitrosamines with LCMS (Liquid Chromatography-Mass Spectrometry). There are 70 samples with NPC, with 
clinical stadium according to AJCC 2010.  Data were also analyzed with SPSS 20 statistical tests and chi-square. 
Results: There is no significant result found within the expression of HLA-A2 with a clinical stage of 
Nasopharyngeal Carcinoma (P =0.554). Therefore, there is no significant correlation between the CYP2E1 gene 
polymorphism with the clinical stage of Nasopharyngeal Carcinoma (P=0.088). Furthermore, there is no 
significant correlation found between the levels of nitrosamines with clinical stage (P=0.079) and there was no 
significant relationship between CYP2E1 gene polymorphism and levels of nitrosamines with clinical stage. 
Moreover, there was no significant relation between the expression of HLA-A2, CYP2E1 gene polymorphism 
and levels of nitrosamines with a history of smoking. 
Conclusion: There was no statistically significant correlation between the expression of HLA-A2, CYP2E1 
gene polymorphism and levels of nitrosamines to the clinical stage of Nasopharyngeal Carcinoma. However, if 
the CT genotype and levels of nitrosamines were detected in the samples obtained, then they have an increased 
progression of 7.2 times greater compared to patients who only had the CT genotype or only detectable levels 
of nitrosamines. 
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Nasopharyngeal carcinoma (NPC) is an malignancy of the upper aerodigestive 
tract epithelium with the most common incidents. NPC is a malignancy in the field 
of Health Science of Ear, Nose and Throat (ENT) which received much attention 
because the mortality rate is still relatively high. Globally, there are approximately 
65,000 new cases and 38,000 deaths per year [1]. 
The highest number obtained in the province of Southeast China is 40-50 
NPC cases among 100,000 residents. For ENT in Indonesia, NPC is in the first 
rank of cancer in the head and neck are with a 2-3:1 comparison between men 
and women [2]. Kuhuwael (2010)  reported in Dadi Hospital and Dr. Wahidin 
Sudirohusodo Hospital, for over 10 years (1990-1999) there had been found 274 
(47.98%) NPC cases with a 2.6:1 comparison between men and women [3].  
Chan (2004) shows an association between loss of alleles on the short arm 
of chromosome 3 and 9 led to inactive genes that suppress tumors, namely p14, 
p15 and p16 [1]. The dysplastic area is the origin of the tumor, but it may not be 
enough to develop further on its own. At this level, latent EBV infection is an 
important point and leads to severe dysplasia. Lanier reported the presence of 
specific haplotypes in the human leukocyte antigen (HLA) which is located on 
the short arm of chromosome 6 that is HLA-A2, HLA-Bsin2, HL B46 which 
increases the risk of NPC, and some other common haplotypes in individuals of 
South China, but rarely on the Caucasian race [6, 7]. 
Although NPC is not included as genetic tumors, susceptibility to NPC in 
certain communities is relatively prominent and it provides an aggregation. 
Familial correlation analysis showed expression of HLA (Human Leukocyte 
Antigen) and encoder gene of the enzyme cytochrome P450 2 E1 (CYP2E1) is 
possibly a susceptibility gene to NPC. Cytochrome P450 2E1 is responsible for 
the metabolic activation of Nitrosamines and related carcinogens. 
Activation of nitrosamines as CYP2E1 substrates can lead to the 
development of various cancers. This has been demonstrated in rats which 
were fed salted fish containing nitrosamines showing progression into the 
nasal cavum tumor. 
The incidence of NPC in areas that consume dishes containing Nitrosamines 
both who live in coastal and mountain areas is high. Therefore, the research on 
environmental factors, especially the consumption of carcinogens needs to be 
investigated in order to do counseling about the NPC in order to reduce the 
incidence of NPC. Besides, research on the relationship of polymorphisms of 
CYP2E1 gene, expression levels of nitrosamines and HLA-A2 in the case of 
NPC patients in Makassar has never been done, so that researchers are interested 
in conducting this research. The data obtained can improve the understanding of 
the pathogenesis of NPC and environmental factors that influence it. 
2. MATERIALS AND METHODS 
This research was conducted at dr. Wahidin Sudirohusodo Hospital and 
Pelamonia Hospital in Makassar, South Sulawesi. Period of research was 
started on February 2013 to January 2014. This research uses a cross-sectional 
design. It uses chi-square statistical test. 
The population of this research is a group of people who suffer NPC at all 
stages according AJCC 2010 and take medication at ENT Polyclinic of dr. 
Wahidin Sudirohusodo Hospital and ENT Polyclinic of Pelamonia Hospital, 
Makassar. Research samples are ranged populations which meet the criteria of 
the research. Sample taking is done through purposive sampling, in which all 
samples meet inclusive criteria until the number of people is fulfilled and ready 
to be included in this research. There are 70 samples obtained. 







In this study, several variables can be identified based on their role 
and scale, such as: 1) The independent variables were HLA-A2 gene 
expression, CYP2E1 gene polymorphism and blood nitrosamine levels; 
2) The dependent variable was the patient with nasopharygeal carcinoma; 
3) The intermediate variable is the process of induction of genetic damage 
due to the activation of nitrosamines by the CYP2E1 gene. 
Examination of HLA-A2 gene using the Immunohistochemistry 
method, the CYP2E1 gene using the Polymerase Chain Reaction method, 
then checking for nitrosamine level using Liquid Chromatography Mass 
Spectrometry (LCMS/MS) method. Interpretation: 1) HLA-A2 gene: 
Positive and Negative; 2) CYP2E1: CC Homozygote and CT 
Heterozygote; 3) Nitrosamine Level : Detected and Undetected. 
Obtained data are processed and the result is presented in tables. 
Statistical analysis is conducted using the SPSS 20 program for windows 
and Chi-Square Statistical Test. Level of significance used is P<0.001 
which means that there is a positive correlation. 
3. RESULTS 
Table 1. Characteristics of NPC Patients in Makassar 
Variable 
               Sample (n=70) 
          n            % 
Age   
20-29 years old 11 15.7 
30-49 years old 37 52.9 
 ≥50 years old 22 31.4 
Sex:     
Male 47 67.1 
Female 23 32.9 
Occupation   
Civil Servant 12 17.1 
Private Employee 1 1.4 
Soldier 2 2.9 
Trader 9 12.9 
Farmer 24 34.3 
Fisherman 1 1.4 
Paddy cab driver 1 1.4 
Housewife 18 25.7 
Student 2 2.9 
Ethnic   
Bugis 31 44.3 
Makassar 12 17.1 
Toraja 11 15.7 
Tolaki 6 8.6 
Bali 3 4.3 
Others 7 10.0 
Table 1 shows the characteristics of NPC patients on 70 research 
samples and it is clear that NPC patients are mostly in the age group of 
30-49 years old (52.9%) and the least is from the age group of 20-29 years 
old (15.7%). Based on gender, NPC patients mostly are males which are 
47 people (67.1%). Based on occupation, NPC patients mostly work as a 
farmer which is 24 people (34.3%), housewife 18 people (25.7%), and 
they are mostly from Bugis ethnic with 31 people (44.3%). 
Table 2. Correlation between HLA-A2 Expression and the Stage of NPC 
patients in Makassar 
HLA-A2 
Expression 
Stage I–III Stage IV Total 
P 
OR 
(95% CI)   n    %   n      %   n     % 
Positive 3 42.9 4 57.1 7 100.0 0.554 1.2 
(0.25-5.92) Negative 24 38.1 39 61.9 63 100.0 
Total 27 38.6 43 61.4 70 100   
Table 2 shows the distribution of patients that have HLA-A2 positive 
expression which is only 7 people, and from those 7 people, there are 4 
(57.1%) who are at stage IV. From the distribution of NPC patients by 
examination of the expression of HLA-A2, they were divided into 2 
groups: positive and negative group in which there were 7 people (10%) 
in positive group and 63 people (90%) in the negative group. OR is 
obtained as 1.2 but was not statistically significant. Those who do not 
have HLA-A2 negative expressions have the risk of progression of 
clinical stage (stage IV) 1.2 times greater than patients who have the 
HLA-A2 expression. 
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Total 27 38.6 43 61.4 70 100   
Table 3 showed 12 patients with detectable nitrosamines. From those 
people, there are 10 (83.3%) at stage IV. OR of 3.8 is obtained but not it is 
not statistically significant. Those who have Detected Nitrosamine level 
potentially have risks of progressivity of clinical stage (stage IV) 3.8 times 
higher than those who have Undetected Nitrosamine level. 




Stage I-III Stage IV Total 
P 
OR 
(95% CI) n % n %   n  % 
Genotype CT 






18 33.3 36 66.7 
54 100.0 
Total 27 38.6 43 61.4 70 100   
Table 4 shows that 54 people have CYP2E1 CC gene polymorphism 
genotype and there are only 16 people with CT genotype. From those 16 
people with CT genotype, there are 7 people (43.8%) who are at stage IV, 
whereas from those 54 people with CC genotype there are 36 people 
(66.7%) at stage IV.  
 Genotype distribution of CYP2E1 gene in patients with NPC showed 
that genotype 2 homozygote genotype CC of 54 people (77.1%) and CT 
heterozygote genotype of 16 people (22.9%). OR obtained is 2.6 but was 
not statistically significant. Those with the CT genotype have an increased 
risk of progression of clinical stage (stage IV) 2.6 times greater than patients 
with the CC genotype.  
Table 5. Distribution of patients according to CYP2E1 gene 




Stage I–III Stage IV Total OR 
(95% CI) 
 n    %  n   %  n      % 
CC and Nitrosamine 
are not detected 
9 64.3 5 35.7 14 100.0 1.0 
CT or Nitrosamine 
are detected 
16 34.8 30 65.2 46 100.0 3.4 (0.97-11.78) 
CT and Nitrosamine 
are detected 
2 20.0 8 80.0 10 100.0 7.2 (1.08-47.96) 
Total 27 38.6 43 61.4 70 100  
Table 5 shows that 14 patients have CT genotype and Undetected 
Nitrosamine, 9 people (64.3%) are at stage 1-3 and 5 people (35.7%) are at 
stage IV. There are 46 patients with CC genotype and Detected Nitrosamine, 
16 people (34.8%) are at stage 1-3 and 30 people (65.2%) are at stage 4. For 
10 patients with CT genotype and Detected Nitrosamine, there are 2 people 
(20%) at stage 1-3 and 8 people (80%) are at stage 4. 
4. DISCUSSION 
This study suggests that NPC significantly occurs to men with 
reproductive age of 30-50 years. This study took NPC patients for HLA-A2 
examination which is one expression of HLA class 1 that shows a high risk to 
develop into NPC [8]. Next is the examination of the CYP2E1 gene 
polymorphism where CYP2E1 is a xenobiotic-metabolizing P450 with 
specific substrates including some industrial chemicals as procarcinogens and 
can trigger NPC. Nitrosamines and inspection levels: in which Nitrosamines 
are among the chemicals contained in the raw materials in the food or tobacco 
which is a pro-carcinogen and can trigger the NPC [7]. Being the most gender 
is male of 47 people (67.1%) with a ratio of 2: 04: 1, which is in line with 
previous studies that more males are involved with a ratio of 1.3: 1. However, 
our study shows that the incidence in men is likely to increase. The most 
significant tribes are Bugis 31 people (44.3%), Makassar 12 people (17.71%) 
and Toraja 11 people (15.7%) which is almost the same to previous studies of 
patients with NPC in Makassar [9]. According to Munir (2007), the population 
in Indonesia is unique due to the process of race assimilation as a result of 
migration or gene flow [10]. Some researchers suggest the similarity patterns 







of HLA genes in Indonesian populations with China. In population genetic 
studies in Jakarta and surrounding areas, it was concluded that the HLA 
antigens on Indonesian population are classified of Mongoloid. Indonesia has 
a population of 3 different sub-races; Sub-race of Paleomongoloid Proto 
Malays, Malay Deutro Paleomongoloid, and Proto Melanesia Bugis Makassar 
is included in sub-race of Paleomongoloid Deutro Malay. In the Javanese 
population which is also from sub-race Paleomongoloid Deutro Malay, the 
people have HLA A2, HLA A11, and HLA A24 [11]. 
The expression of HLA-A2 of patients in Makassar is high which is at 
10%, this is consistent with research on the serotype of HLA-A2, where HLA-
A2 serotype group is very significant, including HLA-A *02 allele which 
consists of HLA - *0201 to *0211. However, HLA-A2 for North America and 
Southeast Asia, the high frequency is HLA-A *0201. Mexico is the highest 
with 54.5%, whereas 10.8% in Southern China. Then Indonesian Javanese in 
Singapore is only 9.0% and the lowest frequency is in Taiwan Saisiat which is 
only 1% (Wikipedia encyclopedia). 
Based on the explanation in table 4, this is not in accordance with the 
study conducted by Dwi from the Biology Department, Medical Faculty, 
University of Indonesia where she found the three genotypes, namely: DD-
DC-CC 70%-26%-2% in patients with NPC and DD-DC-CC 70%-28%-2% 
for the control group [12]. Another study conducted in the population of China, 
Vietnam, and Thailand, there was found a correlation between the D allele with 
individual susceptibility to NPC. It does not apply to the population of 
Indonesia since there were no differences in the ratio between the D and the C 
allele in the control group and the group of NPC [12-16]. In our study, there 
was found no allele T. 
Distribution of nitrosamine level check in NPC patients showed only 12 
people (17.1%) were found to have nitrosamines in the blood, while 58 people 
(82.9%) were not found to have nitrosamines in their blood. This might be due 
to the levels of nitrosamines in samples of blood which is very little or indeed 
no nitrosamines in the blood and is not detected by the tool, so we need a more 
thorough examination or inspection on other nitrosamine compounds such as 
dimethylnitrosamine or diethylnitrosamine [17-20]. 
From the results of the expression of HLA-A2 positive, there are 7 
people with 4 people (51.7%) who had stage IV NPC, and 3 people (42.9%) 
had stage I-III NPC. Lack of expression of HLA-A2 was found, indicating 
that the expression of HLA-A2 is the only genetic marker in a person so that 
not all patients with NPC have the expression of HLA-A2. Other 
possibilities have others besides HLA expression of HLA-A2 as HLA-A11 
and HLA-A24 [21-24]. 
From the examination of the levels of nitrosamines, there was found 
undetectable levels of nitrosamines of 58 people, in which 33 people (56.9%) 
had stage IV NPC and there are 25 people (43.1%) had stage I-III NPC. The 
levels of nitrosamines were detected from 12 people, from which 10 people 
(83.3%) had stage IV and only 2 persons (16.7%) had stage I-III. 
From this study, it can be seen that patients with detectable nitrosamines 
tend to suffer from advanced stage although it is not statistically significant, 
those who have detected nitrosamines have clinical stage progression risk of 
3.8 times greater than patients with no detectable nitrosamines. 
The correlation between gene CYP2E1 genotypes and the clinical stage 
of NPC patients is not statistically significant, but it appears that those with 
the CT genotype had a clinical stage progression of 2.6 times greater than 
those with the CC genotype. This may be due to mutations that accelerate 
further damage [25, 26]. 
From distribution of patients based on gene polymorphisms of 
CYP2E1, Nitrosamine levels, and clinical stage, it can be seen that the CC 
genotype or levels of detected Nitrosamines significantly increase the 
progression of clinical stage of OR=3.4 by itself into OR=7.2 when both 
(genotype CT and Nitrosamines detected with levels) were found in a 
patient. This means that they are the CT genotype of the CYP2E1 gene 
polymorphism with levels of Nitrosamines detected 7.2 times more than in 
stage IV patients who had CT genotype CYP2E1 gene polymorphism as 
well as with no detectable levels of Nitrosamines. 
From the distribution, it is seen that there is a close correlation between 
the CYP2E1 gene polymorphism with nitrosamine levels in the blood. This is 
consistent with the theory that the presence of the CYP2E1 gene that activates 
nitrosamines by increasing xenobiotics to become a Mutagens or pro-
oncogene [27-29]. 
5. CONCLUSION 
From the results of this study it can be concluded that the CT genotype 
of the CYP2E1 gene along with the detected nitrosamines is a risk factor for 
the progression of nasopharyngeal cancer, this proves that there is an 
interaction relationship between genetic factors and enviromental factors in 
the occurrence of nasopharyngeal cancer. 
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